scholarly journals A Case of Painful Hemimasticatory Spasm with Masseter Muscle Hypertrophy Responsive to Botulinum Toxin

2009 ◽  
Vol 2 (2) ◽  
pp. 95-97 ◽  
Author(s):  
Jin-Hyuck Kim ◽  
Seok-Won Han ◽  
Yun Joong Kim ◽  
Jooyong Kim ◽  
Mi-Suh Oh ◽  
...  
Keyword(s):  
Botulinum Toxin ◽  
Masseter Muscle ◽  
Muscle Hypertrophy

scholarly journals Extended effect after a single dose of type A botulinum toxin for asymmetric masseter muscle hypertrophy

2015 ◽  
Vol 48 (02) ◽  
pp. 196-199 ◽  
Author(s):  
Kasturi Bhattacharjee ◽  
Manpreet Singh ◽  
Harsha Bhattacharjee
Keyword(s):  
Botulinum Toxin ◽  
Masseter Muscle ◽  
Muscle Hypertrophy ◽  
Facial Asymmetry ◽  
Type A ◽  
Safe Zone ◽  
Post Injection ◽  
Lower Face ◽  
Facial Contour ◽  
Indian Male

ABSTRACTFacial asymmetry can either be physiological or pathological and is a common cosmetic concern. A 35-year-old Indian male presented with broad appearing lower face and prominent left jaw since adolescence. Parotid enlargement and other local disorders were ruled out. Ultrasonographic thickness of right masseter muscle was 13 mm while that of left was 14.9 mm, in unclenched state. Type-A botulinum toxin (T-ABT) was injected, evenly at five points, in both muscles within the “safe zone”. Using a 29 gauge needle, 15 and 25 international units were delivered to right and left masseters, respectively. Six months post — injection, a reduction of 2.9 mm and 4.4 mm was observed along with a reduced external facial asymmetry. At 24 months, patient maintains a satisfactory facial contour with no significant early or late post-injection complications. Intra-massteric injection of T-ABT can be used effectively as a primary or adjunct procedure for holistic oculo-facial sculpting.

Management of unilateral idiopathic masseter muscle hypertrophy with botulinum toxin type A

2021 ◽  
Vol 14 (1) ◽  
pp. e239056
Author(s):  
Kumar Nilesh ◽  
Ravina Dharamsi ◽  
Pankaj Patil ◽  
Payal Mate
Keyword(s):  
Botulinum Toxin ◽  
Masseter Muscle ◽  
Muscle Hypertrophy ◽  
Botulinum Toxin Type A ◽  
Unknown Origin ◽  
Type A ◽  
Botulinum Toxin Type ◽  
Facial Aesthetics ◽  
Invasive Method ◽  
Bone Injection

Masseter hypertrophy (MH) is an uncommon disorder which can cause both aesthetic and functional problems. The most common aetiological factors associated with MH are habit of chewing gum, clenching and/or bruxism. The treatment of MH includes conservative management as well as surgical resection of the enlarged muscle and/or bone. Injection of botulinum toxin type A is a relatively new and minimally invasive method for management of masseter muscle hypertrophy, which offers many advantages over conventional surgical management. This paper reports a case of unilateral MH of unknown origin which was treated with injection of botulinum toxin type A, resulting in satisfactory reduction in the volume of muscle and improvement of facial aesthetics.

Unilateral Masseter Muscle Hypertrophy: Morphofunctional Analysis of the Relapse After Treatment with Botulinum Toxin

CRANIO® ◽  
2009 ◽  
Vol 27 (3) ◽  
pp. 200-210 ◽  
Author(s):  
Redento Peretta ◽  
Marco Melison ◽  
Roberto Meneghello ◽  
Daniele Comelli ◽  
Luca Guarda ◽  
...  
Keyword(s):  
Botulinum Toxin ◽  
Masseter Muscle ◽  
Muscle Hypertrophy ◽  
Morphofunctional Analysis

Botulinum toxin type A in the management of masseter muscle hypertrophy

2005 ◽  
Vol 63 (1) ◽  
pp. 20-24 ◽  
Author(s):  
Wagner Henriques Castro ◽  
Rodrigo Santiago Gomez ◽  
Jacqueline da Silva Oliveira ◽  
Mariela Dutra Gontijo Moura ◽  
Ricardo Santiago Gomez
Keyword(s):  
Botulinum Toxin ◽  
Masseter Muscle ◽  
Muscle Hypertrophy ◽  
Botulinum Toxin Type A ◽  
Type A ◽  
Botulinum Toxin Type

scholarly journals Biphasic Injection for Masseter Muscle Reduction with Botulinum Toxin

2021 ◽  
Vol 11 (14) ◽  
pp. 6478
Author(s):  
Fabrizio Chirico ◽  
Pierfrancesco Bove ◽  
Romolo Fragola ◽  
Angelo Cosenza ◽  
Nadia De Falco ◽  
...  
Keyword(s):  
Botulinum Toxin ◽  
Masseter Muscle ◽  
Muscle Hypertrophy ◽  
Botulinum Toxin Type A ◽  
Mouth Opening ◽  
Botulinum Toxin Type ◽  
Injection Technique ◽  
Key Factors ◽  
Benign Condition ◽  
Gender Specific

Masseter Muscle Hypertrophy (MMH) is a well-known clinical benign condition that is not gender-specific and it can be monolateral or bilateral. Botulinum Toxin type A (BoNTA) injection has been widely described for MMH treatment and non-surgical facial slimming. BoNTA masseter injections have high efficacy and safety profile, but the risks of side effects remain. Muscular bulging during mastication is a complication due to the superficial overcompensation of masseteric fibers in response to neurotoxic weakening of the deep masseter. We present a biphasic-injection technique for BoNTA administration, based following anatomical concept and developed in order to prevent paradoxical bulging. A total of 98 treatments from 2015 to 2020 were performed with this technique. No remarkable complications occurred in our study. No cases of loss of full smile, difficulty in mouth opening, dizziness, headache, neurapraxia, and xerostomia were reported. A case of asymmetric smiling was self-resolved within a week. No patient claimed transient muscle weakness as distressing. No cases of paradoxical bulging were observed. Extensive knowledge of muscular anatomy and appropriate injection technique are key factors in achieving the desired result and avoiding complications. We feel that sharing this tip could be helpful for all the physicians involved in MMH treatment with BoNTA.

Sign in / Sign up

Export Citation Format

Share Document